It was previously demonstrated that both RAC3 or the splicing Delta 4-SRC3 variant downregulation inhibits the oncogenic potential of cancer cells affecting several pathways related to its activity as a coactivator of nuclear receptors or the cytoplasmic signaling [23]. Here, RAC3 is linked to cancer.